TG Biotech has developed genetic technology around multiple model systems, ranging from animal cell lines to zebrafish and mice to identify and characterize the potential drug targets. In this phase of discovery, we specifically look for information about the metabolic pathway to which the protein target belongs, as well as how it interacts with other members of the pathway, so that we can characterize the target in the context of the entire cell.

In cytoplasm, various enzymes involved in metabolisms of fatty acids, cholesterol and hormones require a large quantity of NADPH for their catalytic activities. So, We hypothesize NADPH-producing enzymes play an important role in supplying NADPH to cytoplasm and ultimately inducing obesity, hyperlipidimia, fatty liver. In consideration of its ablility to produce cytoplasmic NADPH, our target enzyme is expected to be most responsible for the regulation of the supply of NADPH.

After introducing gene (target) into a cell or an animal, TG Biotech identifies intracellular levels of IDPc and its reaction product NADPH have a desicive influence on not only the differentiation rate of adipose cells and lipid deposition in adipose cells, but the biosynthesis of lipids and cholesterol. These symptoms are shown generally in the obesity, hyperlipidemia, fatty liver. Patents for TG Biotech's obesity drug targets-IDPc-have been issued.

Also, TG Biotech identifies key gene regulating cartilage chondrocyte degeneration pathways, and corresponding drug targets, within cells responsible for arthritis. The phenotype of the differentiated chondrocyte is characterized by the synthesis, deposition, and maintenance of cartilage-specific extracellular matrix (ECM) molecules, including type II collagen and proteoglycans such as aggrecan.

copyrights¨Ï2002 TGBiotech Corp. all rights reserved. contact us